Table 1. Tumor growth inhibition rate (TGIR) in nude mouse xenograft model (n = 8 mice/group, mean ± SD).
| Group | 3-week icotinib | 3-week docetaxel | Ending tumor volume (mm3) | TGIR (%) | P value |
|---|---|---|---|---|---|
| Group A | |||||
| Control | Solvent (PBS) | Solvent (PBS) | 920.59 ± 19.11 | ||
| IcoR | 60 mg/kg on day 1,2 | 783.56 ± 12.50 | 16.93 ± 1.49 | < 0.05#,## | |
| IcoH | 1200 mg/kg on day 1,2 | 658.62 ± 7.16 | 32.14 ± 0.86 | < 0.05#,## | |
| DTX | 5 mg/kg on day 1 | 569.61 ± 10.40 | 43.07 ± 1.44 | < 0.05# | |
| Group B | |||||
| IcoR+DTX | 60 mg/kg on day 1,2 | 5 mg/kg on day 1 | 556.83 ± 9.96 | 44.50 ± 1.10 | < 0.05# |
| IcoR-DTX | 60 mg/kg on day 1,2 | 5 mg/kg on day 3 | 572.63 ± 14.91 | 42.78 ± 1.77 | < 0.05# |
| DTX-IcoR | 60 mg/kg on day 2,3 | 5 mg/kg on day 1 | 545.31 ± 6.72 | 45.98 ± 0.85 | < 0.05# |
| Group C | |||||
| IcoH+DTX | 1200 mg/kg on day 1,2 | 5 mg/kg on day 1 | 438.78 ± 5.54 | 58.91 ± 0.71 | < 0.05#,##,▲ |
| IcoH-DTX | 1200 mg/kg on day 1,2 | 5 mg/kg on day 3 | 374.84 ± 16.30 | 66.80 ± 2.05 | < 0.05#,## |
| DTX-IcoH | 1200 mg/kg on day 2,3 | 5 mg/kg on day 1 | 492.03 ± 7.96 | 52.46 ± 0.99 | < 0.05#,##,▲ |
Abbreviations: Control, negative control; DTX, docetaxel; IcoR, a regular icotinib dose; IcoH, a high icotinib dose; IcoH-D, a high icotinib dose and sequential docetaxel for 3 weeks of treatment; IcoR-D, a regular icotinib dose and sequential docetaxel for 3 weeks; IcoH+D, a high icotinib dose plus docetaxel for 3 weeks; IcoR+D, a regular icotinib dose plus docetaxel for 3 weeks; D-IcoR, docetaxel and sequential regular icotinib dose for 3 weeks; D-IcoH, docetaxel and sequential high icotinib dose for 3-week treatment; TGIR, tumor growth inhibition rate.
#P < 0.05 compared to the negative control; ##P < 0.05 compared to docetaxel group; ▲P < 0.05 compared to IcoH-D.